Imeglimin in type 2 diabetes
Copyright 2022 Clarivate..
Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels. When blood glucose levels are inadequately controlled or left untreated, the result is a variety of microvascular and macrovascular complications. To prevent these outcomes, many medications are available to manage type 2 diabetes mellitus and prevent disease progression. However, most of the medications available to date only target a few of the physiological defects caused by diabetes and may come with side effects that make adherence to the medication improbable. Imeglimin, a medication currently under investigation in the United States and approved in Japan, is a novel, first-in-its-class medication with a mechanism that is currently understood to target multiple pathways to provide glycemic control. This review aims to present and discuss the current clinical and scientific evidence pertaining to imeglimin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 58(2022), 9 vom: 27. Sept., Seite 437-449 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huston, Jessica [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.09.2022 Date Revised 16.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2022.58.9.3419555 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346197228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346197228 | ||
| 003 | DE-627 | ||
| 005 | 20231226030837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2022.58.9.3419555 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346197228 | ||
| 035 | |a (NLM)36102904 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huston, Jessica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imeglimin in type 2 diabetes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2022 | ||
| 500 | |a Date Revised 16.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2022 Clarivate. | ||
| 520 | |a Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels. When blood glucose levels are inadequately controlled or left untreated, the result is a variety of microvascular and macrovascular complications. To prevent these outcomes, many medications are available to manage type 2 diabetes mellitus and prevent disease progression. However, most of the medications available to date only target a few of the physiological defects caused by diabetes and may come with side effects that make adherence to the medication improbable. Imeglimin, a medication currently under investigation in the United States and approved in Japan, is a novel, first-in-its-class medication with a mechanism that is currently understood to target multiple pathways to provide glycemic control. This review aims to present and discuss the current clinical and scientific evidence pertaining to imeglimin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AMP-activated protein kinase activators | |
| 650 | 4 | |a Antidiabetic drugs | |
| 650 | 4 | |a Glimins | |
| 650 | 4 | |a Glucose-stimulated insulin secretion | |
| 650 | 4 | |a Imeglimin | |
| 650 | 4 | |a Tetrahydrotriazine-containing antidiabetics | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Triazines |2 NLM | |
| 650 | 7 | |a imeglimin |2 NLM | |
| 650 | 7 | |a UU226QGU97 |2 NLM | |
| 700 | 1 | |a Schaffner, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Langley, Logan |e verfasserin |4 aut | |
| 700 | 1 | |a Skrable, Blake |e verfasserin |4 aut | |
| 700 | 1 | |a Ashchi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Berner, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Gore, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh-Ali, Mae |e verfasserin |4 aut | |
| 700 | 1 | |a Sutton, David |e verfasserin |4 aut | |
| 700 | 1 | |a Goldfaden, Rebecca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 58(2022), 9 vom: 27. Sept., Seite 437-449 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2022 |g number:9 |g day:27 |g month:09 |g pages:437-449 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2022.58.9.3419555 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2022 |e 9 |b 27 |c 09 |h 437-449 | ||